The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Dr Reddys Laboratories Ltd

Dr Reddys Laboratories Ltd

BSE 500124 · NSE DRREDDY · ISIN INE089A01031 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹1,175.00

-0.96%

BSE close, 28 August 2026

Market cap

₹98,069.82 cr

83.5 cr shares · Mid cap

Free float

₹71,459.26 cr

as published

P/E · P/B

147.8× · 3.64×

EPS ₹7.95 · BV ₹322.80

FY25-26 rev / PAT

20,532.80 / 3,219.70

₹ cr, as filed

Filings, window

36

9 selected · 25%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹1,080.05 52-WK HIGH ₹1,414.40 ₹1,175.00 28% of range
Against 52-week high-16.9%
Against 52-week low+8.8%
Day change-0.96%
Size bandMid cap
Index membershipNIFTY 50, NIFTY 500

Valuation as published by BSE

Earnings per share₹7.95
Price / earnings147.80×
Price / book3.64×
Book value — derived, price ÷ P/B₹322.80
Return on equity2.46%
Operating margin17.28%
Net margin7.88%

Consistency check

P/B ÷ P/E, which must equal ROE
2.46%
ROE as published
2.46%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 5,136.60 404.70 4.86 17.28% 7.88%
Mar-26 · Q 3,822.00 -219.40 -2.63 1.76% -5.74%
FY25-26 20,532.80 3,219.70 38.68 27.31% 15.68%

Quarter on quarter

Revenue, quarter on quarter
+34.4%
Net profit, quarter on quarter
+284.5%
Operating margin, quarter on quarter
+1,552 bps

Disclosure profile 36 filings in the window

0 median 17.0 p75 · 25 sector max 52 36 96th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

36 filings · 9 selected · busiest 2026-07-22 and 2026-07-23

Filing rhythm · the twelve most recent

2026-09-102026-10-08

SelectedProcedural

Filings

36 in the window · 20 earlier on record

  1. 8 October 2026 ·

    General

    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / General View filing →

  2. 7 October 2026 ·

    Press Release

    Press Release / Media Release

    Intimation of Earnings call

    Company Update / Press Release / Media Release View filing →

  3. 7 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  4. 22 September 2026 ·

    Trading Window

    Closure of Trading Window

    Closure of Trading window

    Insider Trading / SAST / Closure of Trading Window View filing →

  5. 22 September 2026 ·

    Board Meeting

    Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ending September 30, 2026.

    Dr Reddys Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 ,inter alia, to consider and approve Unaudited Standalone ....

    Board Meeting / Board Meeting View filing →

  6. 21 September 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of analyst meet

    Company Update / Analyst / Investor Meet View filing →

  7. 18 September 2026 ·

    Press Release

    Press Release / Media Release

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / Press Release / Media Release View filing →

  8. 18 September 2026 ·

    General

    Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / General View filing →

  9. 17 September 2026 ·

    Clarification

    Clarification sought from Dr Reddys Laboratories Ltd

    The Exchange has sought clarification from Dr Reddys Laboratories Ltd on September 17, 2026, with reference to news appeared in https://pharma.economictimes.indiatimes.com/ dated September ....

    Company Update / Clarification

  10. 16 September 2026 ·

    Newspaper Publication

    Newspaper Publication

    Copies of newspaper publication

    Company Update / Newspaper Publication View filing →

  11. 11 September 2026 ·

    General

    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / General View filing →

  12. 10 September 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    Allotment of Employee Stock options

    Company Update / Allotment of ESOP / ESPS View filing →

  13. 10 September 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Intimation of Analyst meet

    Company Update / Analyst / Investor Meet View filing →

  14. 26 August 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    Allotment of Employee Stock options

    Company Update / Allotment of ESOP / ESPS View filing →

  15. 20 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Copies of newspaper publication

    Company Update / Newspaper Publication View filing →

  16. 14 August 2026 ·

    General

    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / General View filing →

  17. 14 August 2026 ·

    General

    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / General View filing →

  18. 14 August 2026 ·

    SAST

    Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund

    Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 View filing →

  19. 13 August 2026 ·

    Change in Management

    Change in Management

    Change in Senior Management Personnel

    Company Update / Change in Management View filing →

  20. 7 August 2026 ·

    General

    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2105

    Company Update / General View filing →

  21. 7 August 2026 ·

    General

    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2105

    Company Update / General View filing →

  22. 7 August 2026 ·

    General

    Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / General View filing →

  23. 29 July 2026 ·

    General

    Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / General View filing →

  24. 29 July 2026 ·

    General

    Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / General View filing →

  25. 28 July 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Transcript of Earnings call recording

    Company Update / Analyst / Investor Meet View filing →

  26. 28 July 2026 ·

    Clarification

    Clarification sought from Dr Reddys Laboratories Ltd

    The Exchange has sought clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.business-standard.com dated July 28, 2026, (Link:https://www.business-standard.com/companies/news/dr-reddys-first-in-class-gonorrhoea-drug-gets-thailand-approval-after-us-nod-126072700632_1.html) ....

    Company Update / Clarification

  27. 23 July 2026 ·

    Change in Management

    Change in Management

    Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015

    Company Update / Change in Management View filing →

  28. 23 July 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizer's Report

    AGM/EGM / AGM View filing →

  29. 23 July 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Outcome of 42nd Annual General Meeting

    AGM/EGM / AGM View filing →

  30. 23 July 2026 ·

    Newspaper Publication

    Newspaper Publication

    Copy of newspaper publication

    Company Update / Newspaper Publication View filing →

  31. 23 July 2026 ·

    Press Release

    Press Release / Media Release

    Intimation of Earnings call recordings

    Company Update / Press Release / Media Release View filing →

  32. 22 July 2026 ·

    Investor Presentation

    Investor Presentation

    Copy of Investor Presentation

    Company Update / Investor Presentation View filing →

  33. 22 July 2026 ·

    General

    Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    Grant of Employee Stock Options

    Company Update / General View filing →

  34. 22 July 2026 ·

    Change in Management

    Change in Management

    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

    Company Update / Change in Management View filing →

  35. 22 July 2026 ·

    Results

    Unaudited Financial Results For The Quarter Ended June 30, 2026

    Unaudited Financial results for the quarter ended June 30, 2026

    Result / Financial Results View filing →

  36. 22 July 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting

    Outcome of Board Meeting held on July 22, 2026

    Board Meeting / Outcome of Board Meeting View filing →

RSS feed for Dr Reddys Laboratories Ltd · the 50 most recent filings